Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:MYOV

Myovant Sciences (MYOV) Stock Price, News & Analysis

Myovant Sciences logo

About Myovant Sciences Stock (NYSE:MYOV)

Advanced Chart

Key Stats

Today's Range
$26.98
$27.00
50-Day Range
$26.88
$26.99
52-Week Range
$7.67
$27.06
Volume
2.26 million shs
Average Volume
1.17 million shs
Market Capitalization
$2.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Receive MYOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter.

MYOV Stock News Headlines

Only a handful of people know the setup that's defied these chaotic markets.
Since February, we've hit 28 out of 29 trades – that's a 96% win rate taking simple options setups on one single ticker every day. That's why Jack Carter and I teamed up to reveal The 4PM Payout Plan. Our goal here was to show you how to take these daily setups every morning to collect a 4PM payout. Naturally, no one can guarantee what the market does in the future… But these simple daily options setups have paid out with the market rallying, dropping, or staying flat. And if you want to be one of the few to not just know the ropes behind these daily setups but also deploy them for yourself…
See More Headlines

MYOV Stock Analysis - Frequently Asked Questions

Myovant Sciences Ltd. (NYSE:MYOV) posted its earnings results on Tuesday, October, 26th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.34) by $0.11. The company had revenue of $77.90 million for the quarter, compared to analysts' expectations of $72.67 million.

Myovant Sciences (MYOV) raised $176 million in an initial public offering (IPO) on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Myovant Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

Last Earnings
10/26/2021
Today
5/31/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSE:MYOV
Previous Symbol
NASDAQ:MYOV
Fax
N/A
Employees
407
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$205.98 million
Pretax Margin
-42.81%

Debt

Sales & Book Value

Annual Sales
$230.97 million
Price / Cash Flow
N/A
Book Value
($5.04) per share
Price / Book
-5.35

Miscellaneous

Free Float
95,388,000
Market Cap
$2.62 billion
Optionable
Not Optionable
Beta
2.17

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NYSE:MYOV) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners